Business combinations (Tables)

12 Months Ended

Dec. 31, 2012

Kai Pharmaceuticals [Member]

Business Acquisition [Line Items]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire KAI totaled $332 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):

Indefinite-lived intangible assets - IPR&D	$	240
Goodwill	125
Deferred tax assets (liabilities), net	(59		)
Other assets (liabilities), net	26
Total consideration	$	332

Mustafa Nevzat Pharmaceuticals [Member]

Business Acquisition [Line Items]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire MN totaled $677 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):

Finite-lived intangible assets	$	163
Property, plant and equipment	100
Trade receivables	79
Inventories	52
Goodwill	380
Deferred tax assets (liabilities), net	(45		)
Other assets (liabilities), net	(52		)
Total consideration	$	677

Micromet Inc [Member]

Business Acquisition [Line Items]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire Micromet totaled $1,146 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):

Indefinite-lived intangible assets:
IPR&D	$	440
Contract assets	170
Finite-lived intangible assets — Developed technology	350
Goodwill	330
Cash and marketable securities	154
Deferred tax assets (liabilities), net	(274		)
Other assets (liabilities), net	(24		)
Total consideration	$	1,146

Biovex Group Inc [Member]

Business Acquisition [Line Items]

Aggregate acquisition date consideration to acquire an entity

The aggregate acquisition date consideration to acquire BioVex consisted of (in millions):

Cash paid to former shareholders of BioVex	$	407
Fair value of contingent consideration obligations	190
Total consideration	$	597

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

We allocated the total consideration to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):

Indefinite-lived intangible assets — IPR&D	$	675
Goodwill	170
Deferred tax assets (liabilities), net	(246		)
Other assets (liabilities), net	(2		)
Total consideration	$	597